Pneumonia, Viral
Recent clinical, regulatory, research and industry developments relating to this disease.
Prospects and Challenges in Developing mRNA Vaccines for Infectious Diseases and Oncogenic Viruses.
Microplastics dysregulate innate immunity in the SARS-CoV-2 infected lung.
Airway Epithelial-Derived Immune Mediators in COVID-19.
COVID-19 vaccine BNT162b1 elicits human antibody and T<sub>H</sub>1 T cell responses.
Autoantibodies against type I IFNs in patients with life-threatening COVID-19.
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19.
SARS-CoV-2 vaccines in development.
Neurological associations of COVID-19.
Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19).
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 2 clinical trials with recent milestones.
Clinical MilestonesViewHide
- 2026-07-01Effect of Acyclovir Therapy on the Outcome of Ventilated Patients With Lower Respiratory Tract Infection and Detection of Herpes Simplex Virus in Bronchoalveolar LavagePrimary completion
- 2026-05-01A Randomized, Double-blind, Placebo-controlled, Phase 2a Multiple Ascending Dose Study to Examine the Safety, Tolerability and Efficacy of AV-001 Injection in Patients Hospitalized With Pneumonia Due To COVID-19 or Other Respiratory Infections.Primary completion
- 2026-07-01ClinicalEffect of Acyclovir Therapy on the Outcome of Ventilated Patients With Lower Respiratory Tract Infection and Detection of Herpes Simplex Virus in Bronchoalveolar LavagePrimary completion
- 2026-05-01ClinicalA Randomized, Double-blind, Placebo-controlled, Phase 2a Multiple Ascending Dose Study to Examine the Safety, Tolerability and Efficacy of AV-001 Injection in Patients Hospitalized With Pneumonia Due To COVID-19 or Other Respiratory Infections.Primary completion
Research-associated treatments
Drugs and agents co-studied with this disease across the research literature — associative, not necessarily established treatments. Number shows shared papers.
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Betacoronavirus63
- Pandemics49
- Pneumonia, Viral39
- Coronavirus Infections38
- Coronavirus8
- Mental Health6
- Disease Outbreaks5
- Immunity, Innate5
Leading journals6
- Frontiers in immunology13
- International journal of environmental research and public health8
- PloS one6
- European heart journal5
- JAMA4
- JAMA cardiology4
Leading researchers8
- Wang Y7
- Li Y5
- Wang X5
- Chen Y4
- Liu Y4
- Wang J4
- Wang Z4
- Yang Y4
Affiliations (unnormalised)6
- School of Medicine9
- School of Public Health8
- Icahn School of Medicine at Mount Sinai7
- University of Oxford6
- School of Nursing5
- University of Washington5
Disease biology
Key proteins & gene products studied in this disease. Number shows shared papers.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Viral pneumonia is inflammation of the lung parenchyma caused by a viral infection. The supplied grounding links this disease space strongly to coronavirus-associated respiratory disease, including COVID-19 caused by SARS-CoV-2.
It is caused by viral infection. The grounding specifically supports SARS-CoV-2 as a causative virus in coronavirus-associated acute respiratory disease within this disease area.
The disease involves inflammatory involvement of the lung parenchyma in the setting of viral infection. The grounding also supports viral entry and host-response biology involving ACE2, spike glycoprotein, viral receptors, interferon type I, cytokines, and immune responses including innate and adaptive immunity.
The grounding supports treatment and prevention approaches at the modality level that include vaccines and drug therapy. Co-studied therapies include COVID-19 vaccines and agents such as hydroxychloroquine, tocilizumab, azithromycin, vitamin D, and quercetin, indicating interest in antiviral, immunomodulatory, and supportive pharmacologic strategies.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Inflammation of the lung parenchyma that is caused by a viral infection.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.